The test performs RT-PCR testing for the detection of SARS-CoV-2.
It uses the company’s core digital microfluidics (DMF) technology to reduce the RT-PCR process.
Furthermore, the Finder SARS-CoV-2 test qualitatively detects RNA from the SARS-CoV-2 virus in nasopharyngeal as well as nasal swab samples and provides results in approximately 17 minutes.
Baebies stated that conventional RT-PCR testing results are typically reported after 24 hours.
The Finder SARS-CoV-2 testing platform features a toaster-sized, compact instrument with a mini-tablet for the user interface.
A single-use disposable cartridge is used to run each test.
Baebies co‑founder and CEO Richard West said: “CE Mark is an important regulatory milestone for Baebies to expand the reach of our Finder SARS-CoV-2 test and introduce the power of DMF to new markets across the world.
“Our technology unlocks access to rapid, accurate testing at the point of care, so communities can manage the threat of Covid-19 now and into the future.”
The company noted that the FINDER 1.5 Instrument uses DMF to quickly move discrete droplets by electrical control on the cartridge.
The device helps hospitals, laboratories and other point-of-care settings meet the demand for fast and accurate testing.
It delivers the accuracy of an RT-PCR lab test and the speed of a rapid antigen test.
Baebies has other panels that are currently under development. They will use the same cartridge format on the FINDER 1.5 platform.